On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc, a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) ...

Live On is a campaign that encourages patients to get to know more about neuromodulation options from Medtronic DBS. The campaign seeks to address one of the biggest challenges in Parkinson’s and ...

Medtronic Percept™ DBS therapy is the only sensing-enabled † DBS system available, allowing a physician to use data from a patient’s brain activity to personalize their treatment. Andy says Medtronic ...

Personalized, adaptive deep brain stimulation (aDBS) is safe and effective for controlling motor symptoms over 10 months in adults with Parkinson’s disease (PD), new research showed. The ADAPT-PD ...

Deep brain stimulation, a process in which electrodes stimulate specific brain circuits to reduce motor symptoms, has long helped people with Parkinson’s disease manage their tremors — but a new ...

NEW DELHI, April 27, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, today announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional ...

Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...

NEW DELHI, IN / ACCESS Newswire / April 27, 2026 / Medtronic, a global leader in healthcare technology, today announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation ...